PATENT APPLICATION

I hereby certify that this correspondence is being transmitted to the United States Patent and Trademark Office through EFS-WEB on December 29, 2008.

Reinhart Boerner Van Deuren, s.c.

Reinhart Boerner Van Deuren s.c.				
By: /Linda Kasulke/ Linda Kasulke				
Date: December 29, 2008 IN THE UNITED STATES	PATENT AND TRADEMARK OFFICE			
GROU	P ART UNIT: 1626			
EXAMINER: ANDERSON, REBECCA L.				
In re application of: Louis A. Carpino et al.))			
Application No: 10/577,352				
Filed: 11/22/2006) For: NEW COUPLING AGENTS FOR PEPTIDE SYNTHESIS			
Confirmation No.: 4886				
Attorney Docket No. 10144				
Customer No. 22922	<i>)</i>)			

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO/SB08a ("Form SB08a") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner place his or her initials in the appropriate area on the enclosed Form SB08a, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form SB08a is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

In re Appln. of Louis A. Carpino et al. Application No. 10/577,352

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

The In	formation Disclosure Statement is being filed:			
	within any one of the following time periods: (a) within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 of an international application; (c) before the mailing date of a first Office Action on the merits; or (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.			
	after (a), (b), (c) or (d) above, but before the mailing date of a final action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and includes <i>one</i> of:			
	the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below). or			
	the fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below).			
	after the mailing date of a final action under 37 CFR 1.113 or a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application and on or before payment of the issue fee, and includes the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$180 as se forth in 37 CFR 1.17(p) (see "Fees" below).			
	after the mailing date of a Notice of Allowance under 37 CFR 1.311, and on or befor payment of the issue fee, and within thirty days of receiving each item of informatio contained in the Information Disclosure Statement, and includes the Statement under 37 CFR 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the fee of \$180 a set forth in 37 CFR 1.17(p) (see "Fees" below). NOTE: This is for original applications except applications for a design patent, filed on or after May 29 2000, wherein a paper containing only an Information Disclosure Statement in compliance with 3 CFR 1.97 and 1.98 is being filed.			
Copies	s of the References			
	Copies of all of the references listed on the enclosed Form SB08a are enclosed herewith.			
\boxtimes	Copies of U.S. patents and patent applications that are listed on the accompanying Form SB08a are not enclosed herewith. Copies of other references identified on the accompanying Form SB08a are enclosed herewith.			

In re Appln. of Louis A. Carpino et al. Application No. 10/577,352 Attached to each reference not in the English language is a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3). An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3). \boxtimes A copy of the foreign search report is enclosed herewith. The references listed on the enclosed Form SB08a were previously identified in the parent application(s) of the present application, and copies of the references were furnished at that time. Accordingly, additional copies of the references are not submitted herewith, so as not to burden the file with duplicate copies of references. The Examiner is respectfully requested to carefully review the references in accordance with the requirements set out in the Manual of Patent Examining Procedure. In accordance with 37 CFR 1.98(d), the details of the parent application(s) relied upon for an earlier filing date under 35 USC 120 in which copies of the references were previously furnished are set out below: U.S. APPLICATIONS Status (check one) U.S. APPLICATIONS U.S. FILING DATE PATENTED PENDING ABANDONED Statement under 37 CFR 1.97(e) The undersigned hereby states that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement. The undersigned hereby states that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

Statement under 37 CFR 1.704(d)

The **undersigned** hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

Application No. 10/577,352 Fees **No fee** is owed by the applicant(s). The IDS Fee of \$180 under 37 CFR 1.17(p) is enclosed herewith. Method of Payment of Fees Attached is a check in the amount of \$ Charge Deposit Account No. 18-0882 in the amount of \$180.00. **Authorization to Charge Additional Fees** If any additional fees are owed in connection with this communication, please charge \boxtimes Deposit Account No. 18-0882. **Instructions as to Overpayment** Credit Account No. 18-0882. Refund /Rodney D. DeKruif/ Reg. No. No. 35,853 Rodney D. DeKruif Tel. No.: (414) 298-8360 Reinhart Boerner Van Deuren s.c. Attn: Linda Kasulke, Docket Coordinator 1000 North Water Street, Suite 2100 Milwaukee, WI 53202 Customer No. 22922 Date: December 29, 2008

CERTIFICATE OF TRANSMISSION UNDER 37 CFR 1.8 I hereby certify that this Information Disclosure Statement and all accompanying documents are, on the date indicated below, ⊠ being transmitted to the United States Patent and Trademark Office via the Electronic Filing						
System. Name (Print/Type)	Linda Kasulke					
Signature	/Linda Kasulke/	Date	December 29, 2008			

In re Appln. of Louis A. Carpino et al.